Clinical trials: Diabetes Type I
Type 1 Diabetes
Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological…
- Trial name
- NCT07097818
- Testing
- T1D team, structured education, peer support , and diabetes technologies, Routine Management
- Where
- 10 sites in China
- Volunteers
- 400 people
- Sponsor
- Second Xiangya Hospital of Central South University
Diabetes Mellitus, Type 1
Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity
The proposed mechanistic formula feeding study sets out to identify the mechanism(s) by which an extensively hydrolyzed casein formula is able to protect children at risk for type 1 diabetes (T1D) from beta-cell autoimmunity.
- Trial name
- EDIA (NCT01735123)
- Testing
- dietary intervention
- Where
- Finland
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of Helsinki
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to compare the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of FIAsp…
- Trial name
- NCT01992588
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Insulin Hypoglycemia
Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment
This is a 24-week, open-label, randomized, multi-center trial conducted in three tertiary hospitals. There are three follow-up measures; at baseline, post-intervention at Week 12, and Week 24.
- Conditions
- Diabetes Mellitus, Insulin Hypoglycemia, Insulin-dependent Diabetes Mellitus
- Trial name
- ICT (NCT03112343)
- Testing
- Algorithm-based feedback messages, Personal Health Record
- Where
- South Korea
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1…
- Trial name
- onset®7 (NCT02670915)
- Testing
- Faster-acting insulin aspart, insulin aspart, insulin degludec
- Where
- 155 sites in United States, Bulgaria and 16 more
- Volunteers
- 834 people
- Sponsor
- Novo Nordisk A/S
Molar Incisor Hypomineralization
Prevalence And Severity Of Molar Incisor Hypomineralization Among A Group Of Children With Type I Diabetes Milletus.
Determine the prevalence of molar incisor hypomineralization among a group of children with type I diabetes millutes, its severity and treatment need via clinical examination of children with type I diabetes millutes .
- Trial name
- NCT06342089
- Testing
- Type I diabetes milletus
- Volunteers
- 238 people
- Sponsor
- Cairo University
Hypoglycemia, Diabetes Mellitus, Type 1
The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes
Objective: Because many people with type 1 diabetes drink ethanol and because glucagon is used to treat mild hypoglycaemia, it is essential to determine whether ethanol will impair the effectiveness of glucagon to increase…
- Trial name
- ALCO1 (NCT02881060)
- Testing
- Alcohol
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Hvidovre University Hospital
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily…
- Trial name
- MODIUS (NCT07599982)
- Testing
- MODI Algorithm
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- DreaMed Diabetes
Type 1 Diabetes
Bone Marrow vs Liver as Site for Islet Transplantation
The goal of this study is to evaluate safety and efficacy of bone marrow (BM) as site for pancreatic islet transplantationin humans.
- Trial name
- IsletBOM2 (NCT01722682)
- Testing
- Human pancreatic islet transplantation
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Ospedale San Raffaele
Type 1 Diabetes
11C-5-HTP PET in Clinical Islet Transplantation
In people with type I diabetes, the insulin producing cells in the pancreas have been destroyed. Presently one can only evaluate the function of the graft through laboratory tests, blood sugars and the insulin requirements.
- Trial name
- NCT02689479
- Testing
- Positron-Emission Tomography, 11C-5-HTP, Magnetic Resonance Imaging
- Where
- 2 sites in Sweden
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Type 2, Obesity
I-care: Stimulating Self-management in Patients With Type 2-diabetes
The overall objective of this pilot study is to develop a cost-effective treatment methodology delivered outside of traditional clinical setting, and based on modern technology for patients with diabetes type 2 also suffering…
- Trial name
- I-care (NCT01297049)
- Testing
- Cognitive behavior therapy (CBT)
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo Metropolitan University
Type 1 Diabetes
Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2
Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and is caused by the autoimmune (loss of self tolerance) mediated destruction of the insulin producing pancreatic beta cells thus leading to insulin…
- Trial name
- DILT1D (NCT01827735)
- Testing
- Aldesleukin (Proleukin)
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Diabetes Mellitus, Type 2
A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects
The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of multiple oral doses of DBPR108 in healthy male subjects.
- Trial name
- NCT02163278
- Testing
- DBPR108
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Ketosis Prone Diabetes
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
- Trial name
- NCT06699810
- Testing
- Continuous Glucose Monitoring, Insulin
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
T1D, Type 1 Diabetes (T1D)
Evaluation of a Biopsychosocial System
The goal of this observational study is to evaluate the feasibility of a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for caregivers of children with type 1 diabetes (T1D).
- Conditions
- T1D, Type 1 Diabetes (T1D), Type 1 Diabetes
- Trial name
- NCT07440108
- Testing
- Use of Biopsychosocial Sensing System
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Association Between Sarcopenia And Diabetic Neuropathy In Adults With Type 1 Diabetes, A Pilot Study
Monocentric interventional prospective study to evaluate the prevalence of sarcopenia in adults with type 1 diabetes (T1DM) and to evaluate the association between diabetic neuropathy and sarcopenia in subjects with T1DM; to…
- Trial name
- SARCO_DM1 (NCT06902597)
- Testing
- Dual energy X-ray absorptiometry
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-Insulin-dependent Diabetes Mellitus
Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
A double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of 2 phases; 1) an 8-week lead-in period during which patients followed a diet judged to be within the acceptable guidelines of the ADA, and 2)…
- Trial name
- NCT01582282
- Testing
- 3.4 g psyllium BID, 6.8g psyllium BID
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Procter and Gamble
Diabetes Mellitus, Type 1
Assessment of an iPhone Application on Glycemic Control in Type 1 Diabetes
The purpose of the study is to assess whether an electronic self-management tool, specifically an iPhone application entitled bant, can improve glycemic control in Adolescents who have Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT01899274
- Testing
- bant iPhone application
- Where
- 2 sites in Canada
- Volunteers
- 92 people
- Sponsor
- The Hospital for Sick Children
Type 1 Diabetes
Encapsulated Faecal Microbiota Transplantation to Preserve Residual Beta Cell Function in Type 1 Diabetes Mellitus
In this single arm pilot study it will be investigated whether encapsulated autologous fecal microbiota transplantation may be used to halt the decline in residual beta cell function in individuals with recent onset Type 1…
- Trial name
- ENCAPSULATE (NCT05323162)
- Testing
- encapsulated autologous fecal microbiota transplantation
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Nordin Hanssen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.